CytoMed Therapeutics Ltd [GDTC] stock is trading at $1.97, down -0.51%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The GDTC shares have gain 1.03% over the last week, with a monthly amount drifted -26.77%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CytoMed Therapeutics Ltd [GDTC] stock has fluctuated between $1.65 and $4.05 over the past year. CytoMed Therapeutics Ltd [NASDAQ: GDTC] shares were valued at $1.97 at the most recent close of the market.
Analyzing the GDTC fundamentals
Gross Profit Margin for this corporation currently stands at 1.04% with Operating Profit Margin at -7.15%, Pretax Profit Margin comes in at -9.15%, and Net Profit Margin reading is -9.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.55 and Total Capital is -0.44. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8034 points at the first support level, and at 1.6368 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.2133, and for the 2nd resistance point, it is at 2.4566.
Ratios To Look Out For
For context, CytoMed Therapeutics Ltd’s Current Ratio is 5.81. As well, the Quick Ratio is 5.81, while the Cash Ratio is 4.06. Considering the valuation of this stock, the price to sales ratio is 135.96, the price to book ratio is 4.05.
Transactions by insiders
Recent insider trading involved mDR Ltd, 10% Owner, that happened on Sep 23 ’25 when 54644.0 shares were purchased. 10% Owner, mDR Ltd completed a deal on Jun 23 ’25 to buy 81482.0 shares. Meanwhile, 10% Owner mDR Ltd bought 86410.0 shares on Mar 24 ’25.
